tradingkey.logo
๎™

Anbio Biotechnology

NNNN
32.350USD
+2.100+6.94%
์ข…๊ฐ€ย 12/19, 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
4.65B์‹œ๊ฐ€์ด์•ก
1939.45P/E TTM
๎™

์ž์„ธํ•œ ๋‚ด์šฉ์€ Anbio Biotechnology ํšŒ์‚ฌ

Anbio Biotechnology is a Germany-based medical device company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).

Anbio Biotechnology ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ NNNN
ํšŒ์‚ฌ ์ด๋ฆ„Anbio Biotechnology
์ƒ์žฅ์ผFeb 19, 2025
CEOLau (Michael)
์ง์› ์ˆ˜27
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒFeb 19
์ฃผ์†ŒFriedrich-Ebert-Anlage 49
๋„์‹œFRANKFURT AM MAIN
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€Germany
์šฐํŽธ ๋ฒˆํ˜ธ60308
์ „ํ™”4916096247281
์›น์‚ฌ์ดํŠธhttps://anbiobiotechnology.com/
์ข…๋ชฉ ์ฝ”๋“œ NNNN
์ƒ์žฅ์ผFeb 19, 2025
CEOLau (Michael)

Anbio Biotechnology์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Ms. Nancy Hartzler
Ms. Nancy Hartzler
Independent Director
Independent Director
--
--
Mr. David Hsu
Mr. David Hsu
Independent Director
Independent Director
--
--
Mr. Kenneth Li
Mr. Kenneth Li
Independent Director
Independent Director
--
--
Mr. Michael Lau
Mr. Michael Lau
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Suki Song
Ms. Suki Song
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Cany Xu
Mr. Cany Xu
Executive Director
Executive Director
--
--
Mr. Chris Tiantian
Mr. Chris Tiantian
Chief Business Officer
Chief Business Officer
--
--
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Ms. Nancy Hartzler
Ms. Nancy Hartzler
Independent Director
Independent Director
--
--
Mr. David Hsu
Mr. David Hsu
Independent Director
Independent Director
--
--
Mr. Kenneth Li
Mr. Kenneth Li
Independent Director
Independent Director
--
--
Mr. Michael Lau
Mr. Michael Lau
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Suki Song
Ms. Suki Song
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Cany Xu
Mr. Cany Xu
Executive Director
Executive Director
--
--

์ˆ˜์ต ๋ถ„์„

ํ†ตํ™”: USD๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Oct 6
ํ†ตํ™”: USD๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Oct 6
FY2024
FY2023
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
์ง€์—ญ๋ณ„USD
์ด๋ฆ„
์ˆ˜์ต
๋น„์œจ
European Union
5.62M
68.64%
South America
1.48M
18.02%
Asia Pacific
509.17K
6.22%
Other Regions
472.38K
5.77%
North America
110.51K
1.35%
์‚ฌ์—…๋ณ„
์ง€์—ญ๋ณ„
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ๋ณด์œ  ํ†ต๊ณ„

๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Thu, Dec 4
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Thu, Dec 4
์ฃผ์ฃผ
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Northwestern Mutual Capital, LLC
4.78%
CVC Investment
4.78%
Geode Capital Management, L.L.C.
0.06%
Marshall Wace LLP
0.02%
Morgan Stanley & Co. LLC
0.02%
๊ธฐํƒ€
90.33%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Northwestern Mutual Capital, LLC
4.78%
CVC Investment
4.78%
Geode Capital Management, L.L.C.
0.06%
Marshall Wace LLP
0.02%
Morgan Stanley & Co. LLC
0.02%
๊ธฐํƒ€
90.33%
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
๋น„์œจ
Investment Advisor
4.80%
Corporation
4.78%
Investment Advisor/Hedge Fund
0.08%
Research Firm
0.03%
Hedge Fund
0.02%
Venture Capital
0.02%
๊ธฐํƒ€
90.28%

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Oct 1
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Oct 1
๋ณด๊ณ  ๊ธฐ๊ฐ„
๊ธฐ๊ด€ ์ˆ˜
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
2025Q3
8
2.13M
4.85%
+2.06M
2025Q2
5
4.27M
9.72%
+4.25M
2025Q1
5
4.27M
9.72%
+4.27M

์ฃผ์ฃผ ํ™œ๋™

๎™Œ
์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
Chg %
๋‚ ์งœ
Northwestern Mutual Capital, LLC
2.10M
4.78%
+2.10M
--
Feb 19, 2025
CVC Investment
2.10M
4.78%
+2.10M
--
Feb 19, 2025
Geode Capital Management, L.L.C.
17.13K
0.04%
+70.00
+0.41%
Jun 30, 2025
Marshall Wace LLP
--
0%
-43.63K
-100.00%
Jun 30, 2025
Morgan Stanley & Co. LLC
400.00
0%
+400.00
--
Jun 30, 2025
BNP Paribas Securities Corp. North America
1.26K
0%
+1.26K
--
Jun 30, 2025
UBS Financial Services, Inc.
10.70K
0.02%
+4.96K
+86.39%
Jun 30, 2025
๋” ๋ณด๊ธฐ

๊ด€๋ จ ETF

๎™Œ
์ด๋ฆ„
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ฐฐ๋‹น๊ธˆ

๎™Œ
์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ด 0.00 USD์˜ ๋ฐฐ๋‹น๊ธˆ์ด ๋ถ„๋ฐฐ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
๋‚ ์งœ
๋ฐฐ๋‹น๊ธˆ
๊ธฐ์ค€์ผ
์ง€๊ธ‰์ผ
๋ฐฐ๋‹น๋ฝ์ผ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ถ„ํ• 

๎™Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Anbio Biotechnology์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Anbio Biotechnology์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค:
Northwestern Mutual Capital, LLC๋Š” 2.10M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 4.78%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
CVC Investment๋Š” 2.10M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 4.78%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Geode Capital Management, L.L.C.๋Š” 17.13K์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 0.04%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Marshall Wace LLP๋Š” 0.00์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 0.00%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Morgan Stanley & Co. LLC๋Š” 400.00์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 0.00%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.

Anbio Biotechnology์˜ ์ƒ์œ„ 3๋Œ€ ์ฃผ์ฃผ ์œ ํ˜•์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
Anbio Biotechnology์˜ ์ฃผ์š” ์ฃผ์ฃผ ์œ ํ˜• ์ƒ์œ„ 3๊ฐ€์ง€๋Š”
Northwestern Mutual Capital, LLC
CVC Investment
Geode Capital Management, L.L.C.์ž…๋‹ˆ๋‹ค.

Anbio Biotechnology(NNNN)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2025Q3 ๊ธฐ์ค€์œผ๋กœ, Anbio Biotechnology์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 8๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 2.13M๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 4.85%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q2 ๋Œ€๋น„ -4.87% ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.

Anbio Biotechnology์˜ ์ตœ๋Œ€ ์ˆ˜์ต์›์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
FY2024 ๊ธฐ์ค€, Anbio Biotechnology์˜ -- ๋ถ€๋ฌธ์ด ๊ฐ€์žฅ ๋†’์€ ๋งค์ถœ์„ ๊ธฐ๋กํ–ˆ์œผ๋ฉฐ, ๊ธˆ์•ก์€ --๋กœ ์ „์ฒด ๋งค์ถœ์˜ --%๋ฅผ ์ฐจ์ง€ํ–ˆ์Šต๋‹ˆ๋‹ค.
KeyAI
๎™